This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

WCLC, Barcelona, Spain 7-10 September 2019

Targeting NRG1-fusions in lung adenocarcinoma: afatinib as a novel potential treatment strategy

Michaël Duruisseaux, Janessa J. Laskin, Khaled Tolba, Eva Branden, Yasushi Goto, Robert C. Doebele, Parneet Kaur Cheema, Jacques Cadranel, Martin R. Jones, Alexander E. Drilon, Domenico Trombetta, Lucia A. Muscarella, Agnieszka Cseh, Flavio Solca, Stephen V. Liu 

wclc_2019_duruisseaux_nrg1_lung.jpg

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Targeting NRG1-fusions in lung adenocarcinoma: afatinib as a novel potential treatment strategy

Weinberg et al. ESMO-WCGC 2019 P-291

RELATED INFORMATION

Afatinib

Afatinib (GIOTRIF®) as monotherapy is approved for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s); and locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib

WCLC 2019

Find information on Boehringer Ingelheim’s activities at WCLC 2019
Back to top

FOR HEALTHCARE PROFESSIONALS ONLY.

image